DefenCath® (taurolidine and heparin) catheter lock solution is indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients.

Analyst Coverage

CorMedix is followed by the analysts listed below. Please note that any opinions, estimates or forecasts regarding CorMedix’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of CorMedix or its management.

CorMedix does not by its reference below imply its endorsement of or concurrence with such information, conclusions or recommendations. Furthermore, CorMedix may not and is not obligated to update publicly any such coverage information as changes may occur in the future.

Jason N. Butler, Ph.D.

JMP Securities
(212) 906-3505

Serge Belanger

Needham & Company
(212) 705-0407

Leszek Sulewski

Truist Securities
(212) 303-1745

Gregory Renza, M.D.

RBC Capital Markets
(212) 858-7065